menu
    • menu

    Company profile for Immodulon Therapeutics

    NEW Drugs in Dev: 3
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immodulon Therapeutics Ltd. is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. IMM-101 has a unique mechanism of action that should not only make this innovative product applicable to a large range of cance...
    Immodulon Therapeutics Ltd. is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. IMM-101 has a unique mechanism of action that should not only make this innovative product applicable to a large range of cancers but, in combination with immune checkpoint inhibitors and other standard-of-care treatments, is expected to enhance their efficacy without increasing the safety burden for the patient.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Immodulon Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    6-9 The Square Stockley Park Uxbridge UB11 1FW
    Telephone
    Telephone
    +44 (0) 20 3137 6346
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immodulon.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immodulon-therapeutics-limited/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Precision-Panc Team Opens PRIMUS-006 Study For Gemcitabine, Pembrolizumab
    Precision-Panc Team Opens PRIMUS-006 Study For Gemcitabine, Pembrolizumab

    18 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/18/2900133/0/en/Precision-Panc-Team-Open-the-PRIMUS-006-Study-a-Novel-Combination-of-IMM-101-Gemcitabine-and-Pembrolizumab.html

    GLOBENEWSWIRE
    18 Jun 2024
    Share Share
    Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium
    Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium

    29 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/29/2871164/0/en/Immodulon-to-Participate-in-the-Wells-Fargo-Virtual-Private-Biotech-Symposium.html

    GLOBENEWSWIRE
    29 Apr 2024
    Share Share
    Immodulon Announces Formation of New Scientific Advisory Board
    Immodulon Announces Formation of New Scientific Advisory Board

    11 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/11/2794111/0/en/Immodulon-Announces-Formation-of-New-Scientific-Advisory-Board-to-Support-Late-stage-Clinical-Development-of-IMM-101.html

    GLOBENEWSWIRE
    11 Dec 2023
    Share Share
    Immodulon Appoints Richard Couch as CTO and Owen Vaughan as CRO
    Immodulon Appoints Richard Couch as CTO and Owen Vaughan as CRO

    26 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/26/2694140/0/en/Immodulon-Further-Strengthens-Leadership-Team-with-the-Appointments-of-Richard-Couch-as-Chief-Technology-Officer-and-Owen-Vaughan-as-Chief-Regulatory-Officer.html

    GLOBENEWSWIRE
    26 Jun 2023
    Share Share
    Immodulon, Champalimaud Foundation team up on ‘difficult to treat’ cancers
    Immodulon, Champalimaud Foundation team up on ‘difficult to treat’ cancers

    04 Aug 2020

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/immodulon,_champalimaud_foundation_team_up_on_difficult_to_treat_cancers_1346099

    Lucy Parsons PHARMATIMES
    04 Aug 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search